Von Eschenbach nomination blocked again

Share this article:
Sen. Charles Grassley (R-Iowa) said he would block Andrew von Eschenbach’s confirmation to head the FDA. As a reason for his opposition, Grassley cited von Eschenbach’s failure to comply with subpoenas issued by the Senate Finance Committee, which has oversight over the FDA. In a letter to outgoing Majority Leader Bill Frist (R-Tenn.), Grassley also mentioned that he and Sen. Max Baucus (D-Mont.) had met with HHS Secretary Mike Leavitt to express their objections. Grassley asked Frist to consult him before “entering into any unanimous consent agreement” on von Eschenbach’s nomination, according to Bloomberg News. The letter didn’t describe the subject of the subpoenas, issued in May for access to documents and an agency employee. Grassley’s represents the third hold on the von Eschenbach nomination by a Republican senator. The other two Republican holds have come from Sens. Jim DeMint of South Carolina and David Vitter of Louisiana. DeMint wants the FDA to withdraw abortion drug RU- 486 from the market, while Vitter is trying to get the Bush administration to allow some prescription drug imports. Before DeMint and Vitter moved to block the nomination, Democrats were holding it up over Barr Pharmaceuticals’ application to sell the Plan B contraceptive without a prescription. The FDA cleared the over-the-counter sales in August for women ages 18 and older.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...